Provided by Tiger Trade Technology Pte. Ltd.

Foghorn Therapeutics Inc.

4.49
-0.1800-3.85%
Post-market: 4.41-0.0800-1.78%19:30 EDT
Volume:396.83K
Turnover:1.79M
Market Cap:266.64M
PE:-4.61
High:4.65
Open:4.65
Low:4.46
Close:4.67
52wk High:7.61
52wk Low:3.27
Shares:59.39M
Float Shares:28.08M
Volume Ratio:0.95
T/O Rate:1.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9742
EPS(LYR):-1.1800
ROE:-470.38%
ROA:-19.92%
PB:-3.29
PE(LYR):-3.81

Loading ...

Foghorn presents new preclinical data for SMARCA2 inhibitor FHD-909 at AACR 2026

Reuters
·
Apr 09

Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

GlobeNewswire
·
Apr 09

4D Molecular Therapeutics names CFO Kristian Humer principal accounting officer

Reuters
·
Mar 31

Foghorn Therapeutics Price Target Maintained With a $10.00/Share by Wedbush

Dow Jones
·
Mar 12

Foghorn Therapeutics (FHTX) Receives a Buy from Guggenheim

TIPRANKS
·
Mar 12

Buy Rating on Foghorn Therapeutics Driven by Lilly Partnership Catalyst, Advancing Degrader Pipeline, and Strengthened Cash Runway

TIPRANKS
·
Mar 12

Foghorn Advances FHD-909 Trial and Strengthens Financial Position

TIPRANKS
·
Mar 12

Foghorn Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 12

Foghorn Therapeutics Q4 EPS $(0.34) Misses $(0.27) Estimate, Sales $9.247M Miss $9.500M Estimate

Benzinga Earnings
·
Mar 12

Foghorn Therapeutics FY 2025 collaboration revenues rise 37% to USD 30.9 million, net loss narrows 14% to USD 74.3 million

Reuters
·
Mar 12

Press Release: Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Dow Jones
·
Mar 12

Foghorn Therapeutics Price Target Maintained With a $13.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 10

Foghorn Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview

Reuters
·
Mar 07

Foghorn Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview

Reuters
·
Mar 03

Foghorn Therapeutics Files Initial Beneficial Ownership Statement for CFO Ryan D. Maynard

Reuters
·
Feb 25

Foghorn Therapeutics to Present at TD Cowen Annual Health Care Conference and Citizens Life Sciences Conference

Reuters
·
Feb 24